FEDERALSEC 10-K Item 1CFirst filing
Filed Feb 24, 2026bd_ce9969ddac391169
Corcept Therapeutics Inc. reports in its 10-K Item 1C that no cybersecurity threats have occurred that materially impacted its business, results of operations, or financial condition. The company describes its cybersecurity risk management, strategy, and governance, including the use of managed detection and response, multi-factor authentication, penetration testing, and third-party assessments. The Audit Committee of the Board of Directors oversees cybersecurity risks.